Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    500 Collins Street
    Level 15
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    11

Stocks News & Analysis

stocks

SpaceX is scaling AI infrastructure on earth, data centers in space might be next

Our view on the first results as a publicly traded company.
stocks

A look into newly listed Glencore’s valuation

A new ASX heavyweight with coal, copper and trading exposure.
stocks

Meta is up 9% this year. Is it still a buy ahead of earnings?

We’ll be watching Muse agent adoption, revenue growth, and more.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,956.6012.400.14%
CAC 407,921.6883.191.06%
DAX 4025,645.04340.621.35%
Dow JONES (US)52,621.18125.300.24%
FTSE 10010,752.8819.880.19%
HKSE23,651.87215.87-0.90%
NASDAQ26,624.18199.370.75%
Nikkei 22564,621.24545.820.85%
NZX 50 Index13,761.29129.600.95%
S&P 5007,738.0625.490.33%
S&P/ASX 2008,831.3014.400.16%
SSE Composite Index3,713.0322.34-0.60%

Market Movers